Skin innate immune system in psoriasis: friend or foe?

Brian J. Nickoloff
Department of Pathology and Department of Microbiology and Immunology,
Loyola University of Chicago, Cardinal Bernardin Cancer Center, 2160 South First Avenue, Room 301,
Maywood, Illinois 60153-5385, USA. Phone: (708) 327-3241; Fax: (708) 327-3239; E-mail: Bnickol@luc.edu.

Immunobiological and genetic approaches to understand psoriasis are rapidly converging. Psoriasis is a common inherited disease that has been described for 2000 years, and affects 2–3% of the world-wide population. Immunologists, cell biologists, and molecular geneticists are becoming increasingly preoccupied with the cellular and molecular events that produce the commotion in the epidermis that results in a psoriatic plaque. Dermatologists familiar with this enigmatic and chronic disorder recognize that emergence of the distinctive phenotype (widely scattered erythematous plaques; Figure 1) is likely to be multifactorial, related to both environmental and genetic triggering factors (1). Psoriasis currently tops the list, based on population frequencies and familial clustering, of human autoimmune and immune-related diseases (2).

Despite its accessibility, frequency, and persistence since antiquity, many puzzling questions about psoriasis remain unanswered. Perhaps the most obvious unresolved issue, reflecting the lack of an identification of the major genetic susceptibility determinants, is whether this disorder fundamentally reflects an abnormality in the epidermal keratinocyte (KC) or bone-marrow derived immunocyte. This distinction becomes blurred because of cross-talk between activated KCs and immunocytes that begins immediately upon lesion formation and culminates in the mature psoriatic plaque. This uncertainty prompts further questions: Does psoriasis represent a primary defect in the terminal differentiation response to injury by KCs that fail to produce a normal stratum corneum and, therefore, do not create a protective physiological barrier? Alternatively, is the aberrant KC differentiation program in psoriasis a consequence of an influx of pathogenic immunocytes participating in a rogue auto-immune reaction? These possibilities are relevant to our understanding of the hyperresponsiveness of pre-psoriatic skin reported by Travers et al. in this issue of the JCI (3). In this Commentary, I synthesize available data into a multistep model, taking a novel view of psoriasis from the perspective of the innate immune system. This approach may lead to new avenues for investigators confronting this perplexing skin problem that involves dynamic and reversible epidermal remodeling.

Role of innate immunity in adaptive response of skin

Since few other organ systems are as constantly confronted by potentially life-threatening infectious agents, it should not be surprising that many cutaneous protective strategies have evolved involving both innate and acquired immunity. The primary intrinsic anti-infectious protective shield of the skin is the stratum corneum, a non-viable surface layer of “mummified” anucleated cells derived from terminally differentiated KCs. The stratum corneum consists of highly cross-linked proteinaceous cellular envelopes with extracellular lipid lamellae, consisting mainly of ceramides, free fatty acids, and cholesterol (4). This biological “Saran Wrap” can be removed by repeated cellophane tape stripping to perturb the barrier function (Figure 2), altering transepidermal water loss and calcium ion gradients. Such mild trauma renders the skin permeable to infectious agents and/or their secreted products such as bacteria-derived super-antigens (SAg’s). One of the immediate protective responses of skin to barrier perturbation is release of lamellar bodies (LB) containing pre-formed lipid and hydrolytic enzymes, as well as cytokines such as TNF-α and IL-1 (5, 6). Other early events include influx of neutrophils that release anti-microbial agents, production of anti-bacterial defensins by KCs, and enhanced desquamation of the stratum corneum itself (7). In healthy individuals, these innate responses quickly restore cutaneous homeostasis, but in genetically predisposed patients with psoriasis, new lesions are created that can persist for decades. Because of the aberrant epidermal differentiation program in such lesions, psoriatic plaques lack a normal granular cell layer or intact stratum corneum (8). Despite this compromised structural shield, however, the fully-developed psoriatic plaque is resistant to invasion by infectious organisms (9).

One possible explanation for this resistance to infection involves a compensatory response by members of the cellular immune system, particularly T cells expressing natural killer receptors (NKR). There are 3 principle reasons for considering immunocytes in the pathogenesis of psoriasis. First, many different types of barrier defects in the epidermis have been produced in transgenic mice that do not produce a psoriatic plaque. For example, in keratin-10 knockout mice, although hyperkeratosis occurs as the animals mature, other stigmata of psoriasis, such as loss of the...
granular cell layer, elongation of rete pegs, or an angiogenic tissue reaction, are not present (10). Thus, as current dogma now suggests, the barrier defect in psoriasis more likely represents a consequence, rather than a cause, of infiltration by activated immunocytes that release cytokines that trigger an aberrant differentiation program in the epidermis (11). Second, many drugs that selectively target activated T cells are very effective in producing remissions in psoriasis patients (12). Third, after an upper respiratory infection, psoriatic patients will develop numerous skin lesions that do not represent primary cutaneous infections. As discussed below, this finding suggests that activated immunocytes responsive to the initial bacterial infection can exit the pharynx and migrate to skin where they produce Th1-type cytokines (11). Similarly, transgenic mice that constitutively produce gamma interferon (IFN-γ) in the epidermis, display profound barrier defects in the skin (13); intradermal injection of IFN-γ can also trigger psoriatic lesions in genetically susceptible patients (14). Interestingly, the altered keratin profile seen in keratin 10 knockout mice with disrupted barrier includes aberrant expression of keratin 17, which is also characteristically present in psoriatic plaques (15) and can be induced by exposure to IFN-γ either in-vivo (13) or in-vitro (16).

The innate immunity-based model of psoriasis

Given the prevalence of psoriasis worldwide there may be overlooked beneficial attributes for this genotype. There are many examples in which genetic abnormalities are linked to pathogen resistance (17). While it would be difficult to convince most patients with psoriasis that their disease is actually a blessing rather than a burden, it does appear that formation of a psoriatic plaque provides a rather impressive protective shield for the skin. Because it is clear that the barrier function of normal skin can be acutely breached or, as in psoriasis, chronically altered, we can ask what secondary host-response follows this epidermal defect. Innate immune-based reactions suggest a back-up system distinct from the aforementioned KC-and neutrophil-based responses. Recently, we uncovered in skin a previously overlooked subset of T cells that express surface receptors typically present on natural killer (NK) cells (18, 19). These receptors (NKRs) are on lymphocytes that also express T-cell receptors (TCRs), and such cells (i.e., NK-T cells) may represent a link between the

---

Figure 2

Schematic representation depicting how a confederacy of innate immunity-based genes and cells may conspire to create a psoriatic lesion. Whether triggered by an exogenous event that disrupts KC barrier function (with or without bacterial infection) or by an endogenously-derived infiltration of activated immunocytes, the final mature psoriatic plaque includes an epidermal compartment resistant to infections, apoptosis, and transformation. The complexity of interactions between innate immunity and acquired immunity in skin is depicted as a multi-step model highlighting 2 key abnormalities in psoriasis, including (a) defective terminal differentiation/barrier function and (b) hyperreactivity of the skin immune system including T cells bearing NKRs, which can evolve into a full-fledged Th1-type cell-mediated reaction involving adaptive immune components.

---
that certain glycolipids, such as α-galactosylceramide, enhance the CD1d-related NK-T-cell production of IFN-γ. Upon barrier disruption, it is likely that bacterial SAg’s reach into the mid- and lower epidermis and that a variety of glycolipid antigens are unveiled during keratinocyte-mediated TNF-α production. Thus, once NKR-bearing T cells reach a critical threshold in the bloodstream, they can enter the skin and, upon contact with CD1d-bearing KCs, upregulate production of IFN-γ, a cytokine that triggers an aberrant differentiation program in the epidermis. This “inside-out” creation of a new psoriatic lesion would proceed following the same cytokine cascade that results from physical disruption of the stratum corneum. Thus, defensive barrier formation by KCs and an exaggerated NK-T cell response conspire to produce a psoriatic plaque, which solves the primum movens of psoriasis, beginning with inflammatory-type reactions involving innate immunity and activation of T-cell activation (23), the precise timing of the therapeutic intervention becomes important in treating early, evolving lesions rather than established plaques. In contrast to the use of non-specific immunomodulatory agents the emphasis based on this model is to develop targeted methods to reverse the hyperresponsiveness of psoriatic skin. Therapies to influence barrier function might include drugs that promote terminal differentiation even in the presence of cytokines such as TNF-α and IFN-γ (i.e., peroxisome proliferator-activated receptors; PPAR activators) (24). To block either NK-T- or conventional T-cell activation, and hence to reduce IFN-γ production, it may be possible to block TCR-based or NKR-based signaling using specific mAb’s, or to interfere with additional costimulatory molecules using CTLA4Ig (25) or anti-LFA-1/ICAM-1 mAb’s (26). Finally, blocking or interrupting the angiogenic switch, particularly involving vascular endothelial growth factor-mediated neovascularization (VEGF-mediated) neovascularization, represents another therapeutic opportunity in psoriasis.

**Future direction and challenges**

Clearly an incontrovertible view of psoriasis will emerge by correctly identifying all genetic mutations and by elucidation of the molecular pathway responsible for masterminding this multicellular conspiracy in skin. While several candidate gene loci have been proposed in psoriasis (9), only 2 regions will be discussed. One region is within the MHC complex on 6p21.3 (27) and includes the non-HLA gene—encoding corneodesmosin (CD)—a protein with homology to keratin-10 (28, 29). The other region includes a cluster of genes on chromosome 1q21 (30). Potential candidate genes encode markers of epidermal differentiation such as corneodesmosin, psoriasin, and CD1d, to name a few (18, 30, 31). It should be noted that corneodesmosin was not initially considered to have an immunological function (and...
hence perhaps was misplaced in the genome amidst other important immune responsive genes including the MHC class I and II antigens, complement proteins, and potent immunomodulatory cytokines), but its location at 6p21 may reflect its role in formation of stratum corneum — the primary immunological defensive shield for the entire body.

Besides these genetic approaches, it is clear that more work is required to better understand how innate immunity can affect adaptive immune responses (32, 33) and to unravel the basis of the hyperresponsiveness of pre-psoriatic skin. It will be of critical importance to compare phenotypic profiles and function of relevant ligand/receptors mediating activation of T cells bearing NKRs between individuals with and without psoriasis. Molecular pairs of interest include NKRs interacting with class I MHC alleles (i.e., Cw6); CD158, MICa (NKGD2), CD1d reactive TCR/costimulatory molecule CD161, and CD94/NKG2 receptors for HLA-E-bound peptides (12). An intriguing line of investigation will be to determine if patients have mutations that prompt an exaggerated or dysregulated interaction between NK-T cells and epidermis. It is also possible that, besides involvement of glycolipids and lectin-like NKRs on these T cells, there are also peptide-bound antigens in stratum corneum which contribute to persistence and/or evolution of initial lesions into conventional full-fledged T cell-mediated reactions (34). Epitope spreading involving other self-antigens including peptide antigens that participate in enhanced immune responses may also be considered in chronic T cell–mediated dermatitis. In addition to resisting infection, plaque KCs resist apoptosis as one aspect of serving as a protective shield (12). Plaques also resist transformation despite exposure to initiators and promoters such as anthralin, crude coal tar, UV-light, and chronic immune suppression (35). Taken together, the KCs in psoriatic plaques follow an aberrant differentiation pathway and resist apoptosis and transformation, features that resemble the state of cellular senescence (12).

In summary, psoriasis is a complex and highly dynamic disease process likely to continue to challenge our scientific approaches and imagination. Even though many dermatologists continue to treat psoriasis with relatively nonspecific immunosuppressive drugs, I hope this Commentary prompts exploration of new therapeutic approaches and rethinking regarding the role of innate versus acquired immunity in the skin. In any event, the aforementioned observations suggest that we should broaden our viewpoint as to what constitutes innate immunity in skin and its relevance to psoriasis.

Acknowledgments

Many thanks to members of the Loyola University Skin Cancer Program for helpful discussions; Heide Bauer, Crystal Tabor, and Brian Bonish for preparation of figures; and Theresa Hermann for manuscript preparation. June Robinson supplied the clinical photograph. Craig Thompson reviewed the manuscript, and John Ashkenas provided valuable criticism. The author acknowledges the National Institutes of Health for 15 years of grant support related to psoriasis.